Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Short‐ and long‐term effectiveness of enteral and parenteral nutrition in reversing or preventing protein‐energy malnutrition in advanced neuroblastoma a prospective randomized study

Short‐ and long‐term effectiveness of enteral and parenteral nutrition in reversing or preventing... The effectiveness of enteral and parenteral nutrition regimens in preventing or reversing protein–energy malnutrition (PEM) and in preventing treatment delays was evaluated in 32 children receiving treatment for newly diagnosed Stage III (3 patients) and IV (29 patients) neuroblastoma. Ten of 18 malnourished patients were randomized to central parenteral nutrition (CPN) and 8 to peripheral parenteral nutrition (PPN) plus enteral nutrition for 4 weeks and then received enteral nutrition (EN: intense nutrition counselling, oral foods and supplements) for weeks 5 through 10. Ten of 14 nourished patients received EN and 4 CPN for 4 weeks and EN thereafter. Dietary, anthropometric and biochemical measurements were determined for weeks 0, 1, 2, 3, 4, 7, and 10 for 24 patients who completed the protocols. In malnourished patients, both CPN (seven patients) and PPN (seven patients) were effective in reversing PEM in the first 4 weeks; thereafter, EN effectively maintained nutritional gains in both groups. In nourished patients, EN (seven patients) was not as effective as CPN (three patients) in preventing PEM during the first 4 weeks; afterwards, EN maintained gains in the CPN group but did not promote needed increases in weight nor fat reserves in the EN group. Patients supported by parenteral nutrition (PN, weeks 1–4) had fewer treatment delays (2/17, 12%) than EN patients (4/7, 57%, P <0.05). These data indicate that PN reverses or prevents PEM and prevents treatment delays during the first 4 weeks of intense oncologic treatment and provides nutritional benefits which can be maintained with EN thereafter. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Wiley

Short‐ and long‐term effectiveness of enteral and parenteral nutrition in reversing or preventing protein‐energy malnutrition in advanced neuroblastoma a prospective randomized study

Loading next page...
 
/lp/wiley/short-and-long-term-effectiveness-of-enteral-and-parenteral-nutrition-uLWWGtlLtL

References (62)

Publisher
Wiley
Copyright
Copyright © 1985 American Cancer Society
ISSN
0008-543X
eISSN
1097-0142
DOI
10.1002/1097-0142(19851215)56:12<2881::AID-CNCR2820561228>3.0.CO;2-7
Publisher site
See Article on Publisher Site

Abstract

The effectiveness of enteral and parenteral nutrition regimens in preventing or reversing protein–energy malnutrition (PEM) and in preventing treatment delays was evaluated in 32 children receiving treatment for newly diagnosed Stage III (3 patients) and IV (29 patients) neuroblastoma. Ten of 18 malnourished patients were randomized to central parenteral nutrition (CPN) and 8 to peripheral parenteral nutrition (PPN) plus enteral nutrition for 4 weeks and then received enteral nutrition (EN: intense nutrition counselling, oral foods and supplements) for weeks 5 through 10. Ten of 14 nourished patients received EN and 4 CPN for 4 weeks and EN thereafter. Dietary, anthropometric and biochemical measurements were determined for weeks 0, 1, 2, 3, 4, 7, and 10 for 24 patients who completed the protocols. In malnourished patients, both CPN (seven patients) and PPN (seven patients) were effective in reversing PEM in the first 4 weeks; thereafter, EN effectively maintained nutritional gains in both groups. In nourished patients, EN (seven patients) was not as effective as CPN (three patients) in preventing PEM during the first 4 weeks; afterwards, EN maintained gains in the CPN group but did not promote needed increases in weight nor fat reserves in the EN group. Patients supported by parenteral nutrition (PN, weeks 1–4) had fewer treatment delays (2/17, 12%) than EN patients (4/7, 57%, P <0.05). These data indicate that PN reverses or prevents PEM and prevents treatment delays during the first 4 weeks of intense oncologic treatment and provides nutritional benefits which can be maintained with EN thereafter.

Journal

CancerWiley

Published: Dec 15, 1985

There are no references for this article.